Is There Any Benefit to the Use of Antibiotics with Indwelling Catheters after Urologic Surgery in Adults
Abstract
:1. Introduction
1.1. The Association between Indwelling Catheters, Bacteriuria, and Infection
1.2. Societal Recommendations and Guidelines on Antibiotic Prophylaxis in Urology
2. Materials and Methods
2.1. Aim/Purpose
2.2. Review Framework
2.2.1. Types of Studies
2.2.2. Participants
2.2.3. Interventions and Comparisons
2.2.4. Article Search
2.2.5. Outcomes
3. Results
3.1. Radical Prostatectomy
3.2. Transurethral Resection of the Prostate (TURP)
3.3. Urethroplasty
4. Discussion
5. Conclusions
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- Wazait, H.; van der Meullen, J.; Patel, H.; Brown, C.; Gadgil, S.; Miller, R.; Kelsey, M.; Emberton, M. Antibiotics on urethral catheter withdrawal: A hit and miss affair. J. Hosp. Infect. 2004, 58, 297–302. [Google Scholar] [CrossRef] [PubMed]
- McDonald, M.L.; Buckley, J. Antimicrobial Practice Patterns for Urethroplasty: Opportunity for Improved Stewardship. Urology 2016, 94, 237–245. [Google Scholar] [CrossRef] [PubMed]
- Hoare, D.T.; Doiron, R.C.; Rourke, K.F. Determining Perioperative Practice Patterns in Urethroplasty: A Survey of Genitourinary Reconstructive Surgeons. Urology 2021, 156, 263–270. [Google Scholar] [CrossRef] [PubMed]
- Köves, B.; Tenke, P.; Tandogdu, Z.; Cai, T.; Bogenhard, F.; Wullt, B.; Naber, K.; Bartoletti, R.; Cek, M.; Kulchavenya, E.; et al. Transurethral Resection of the Prostate: Are We Following the Guidelines?—Outcomes from the Global Prevalence of Infections in Urology (GPIU) Study. J. Chemother. 2019, 31, 15–22. [Google Scholar] [CrossRef]
- Umscheid, C.A.; Mitchell, M.D.; Doshi, J.A.; Agarwal, R.; Williams, K.; Brennan, P.J. Estimating the Proportion of Healthcare-Associated Infections That Are Reasonably Preventable and the Related Mortality and Costs. Infect. Control. Hosp. Epidemiol. 2011, 32, 101–114. [Google Scholar] [CrossRef]
- Gould, C.V.; Umscheid, C.A.; Agarwal, R.K.; Kuntz, G.; Pegues, D.A. Healthcare Infection Control Practices Advisory Committee. Guideline for prevention of catheter-associated urinary tract infections 2009. Infect. Control. Hosp. Epidemiol. 2010, 31, 319–326. [Google Scholar] [CrossRef] [Green Version]
- Hooton, T.M.; Bradley, S.F.; Cardenas, D.D.; Colgan, R.; Geerlings, S.E.; Rice, J.C.; Saint, S.; Schaeffer, A.J.; Tambayh, P.A.; Tenke, P.; et al. Diagnosis, prevention, and treatment of catheter-aassociated urinary tract infection in adults: 2009 international clinical practice guidelines from the infectious diseases society of America. Clin. Infect. Dis. 2010, 50, 625–663. [Google Scholar] [CrossRef] [Green Version]
- Bonkat, G.; Bartoletti, R.; Bruyère, F.; Cai, T.; Geerlings, S.E.; Köves, B.; Schubert, S.; Pilatz, A.; Veeratterapillay, R.; Wagenlehner, F.; et al. EAU Guidelines on Urological Infections. Available online: https://uroweb.org/guidelines/urological-infections (accessed on 31 December 2022).
- Lusardi, G.; Lipp, A.; Shaw, C. Antibiotic prophylaxis for short-term catheter bladder drainage in adults. Cochrane Database Syst. Rev. 2013, 2013, CD005428. [Google Scholar] [CrossRef]
- Niël-Weise, B.S.; van den Broek, P.J.; da Silva, E.M.; Silva, L.A. Urinary catheter policies for long-term bladder drainage. Cochrane Database Syst. Rev. 2012, 2012, CD004201. [Google Scholar] [CrossRef]
- Lightner, D.J.; Wymer, K.; Sanchez, J.; Kavoussi, L. Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis. J. Urol. 2020, 203, 351–356. [Google Scholar] [CrossRef]
- E Nicolle, L.; Gupta, K.; Bradley, S.F.; Colgan, R.; DeMuri, G.P.; Drekonja, D.; O Eckert, L.; E Geerlings, S.; Köves, B.; Hooton, T.M.; et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2019, 68, e83–e110. [Google Scholar] [CrossRef] [PubMed]
- Bonkat, G.; Widmer, A.F.; Rieken, M.; Van Der Merwe, A.; Braissant, O.; Müller, G.; Wyler, S.; Frei, R.; Gasser, T.C.; Bachmann, A. Microbial biofilm formation and catheter-associated bacteriuria in patients with suprapubic catheterisation. World J. Urol. 2013, 31, 565–571. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tambyah, P.A. Catheter-associated urinary tract infections: Diagnosis and prophylaxis. Int. J. Antimicrob. Agents 2004, 24, 44–48. [Google Scholar] [CrossRef] [PubMed]
- Sedor, J.; Mulholland, S.G. Hospital-acquired urinary tract infections associated with the indwelling catheter. Urol. Clin. N. Am. 1999, 26, 821–828. [Google Scholar] [CrossRef]
- Hidron, A.; Edwards, J.; Patel, J.; Horan, T. Update: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare. Infect. Control. Hosp. 2008, 29, 996–1011. [Google Scholar] [CrossRef] [Green Version]
- Hall-Stoodley, L.; Costerton, J.W.; Stoodley, P. Bacterial biofilms: From the natural environment to infectious diseases. Nat. Rev. Microbiol. 2004, 2, 95–108. [Google Scholar] [CrossRef] [PubMed]
- Stickler, D.J. Bacterial biofilms in patients with indwelling urinary catheters. Nat. Rev. Endocrinol. 2008, 5, 598–608. [Google Scholar] [CrossRef]
- Saint, S. Clinical and economic consequences of nosocomial catheter-related bacteriuria. Am. J. Infect. Control. 2000, 28, 68–75. [Google Scholar] [CrossRef]
- Tambyah, P.A.; Maki, D.G. Catheter-associated urinary tract infection is rarely symptomatic: A prospective study of 1,497 catheterized patients. Arch. Intern. Med. 2000, 160, 678–682. [Google Scholar] [CrossRef] [Green Version]
- Platt, R.; Polk, B.F.; Murdock, B.; Rosner, B. Mortality Associated with Nosocomial Urinary-Tract Infection. N. Engl. J. Med. 1982, 307, 637–642. [Google Scholar] [CrossRef]
- Healthcare-associated Infections (HAI). Preventing HAIs: Urine Culture Stewardship. CDC. Available online: https://www.cdc.gov/hai/prevent/cauti/indwelling/overview.html#anchor_1554900744. (accessed on 31 December 2022).
- National Healthcare Safety Network. Urinary Tract Infection (Catheter-Associated Urinary Tract Infection [CAUTI] and Non-Catheter-Associated Urinary Tract Infection [UTI]) Events. CDC. Available online: https://www.cdc.gov/nhsn/pdfs/pscmanual/7psccauticurrent.pdf (accessed on 31 December 2022).
- Anger, J.; Lee, U.; Ackerman, A.L.; Chou, R.; Chughtai, B.; Clemens, J.Q.; Hickling, D.; Kapoor, A.; Kenton, K.S.; Kaufman, M.R.; et al. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. J. Urol. 2019, 202, 282–289. [Google Scholar] [CrossRef] [PubMed]
- Lane, G.; Powell, C.R. AUA Core Curriculum: Urinary Tract Infection (Adult). AUA. 2022. Available online: https://university.auanet.org/core/core.cfm?sectionID=92&ct=99a81fed6e38ad2f04e4b0e04028f76aed79ba47dbecfb7a06a5bf4014c951ca9e5444e2e354e37ca2eae0d1a96a0750452c4d0298b9ff2fd5b0c917263f1fbb&ct=7ffaf6ad57e97a99a898c3c75a0fa59fef30890ae25b5460f00fe50b9d9399321e49fd5e62ad89cce232106e0d82b356cfdfad647adb0d7e79c710bb928be21e#ref_4391 (accessed on 31 December 2022).
- Umscheid, C.A.; Agarwal, R.K.; Brennan, P.J. Updating the guideline development methodology of the Healthcare Infection Control Practices Advisory Committee (HICPAC). Am. J. Infect. Control. 2010, 38, 264–273. [Google Scholar] [CrossRef] [PubMed]
- Givens, C.D.; Wenzel, R.P. Catheter-associated urinary tract infections in surgical patients: A controlled study on the excess morbidity and costs. J. Urol. 1980, 124, 646–648. [Google Scholar] [CrossRef]
- Klevens, R.M.; Edwards, J.R.; Richards, C.L., Jr.; Horan, T.C.; Gaynes, R.P.; Pollock, D.A.; Cardo, D.M. Estimating health care-associated infections and deaths in U.S. Hospitals, 2002. Public Health Rep. 2007, 122, 160–166. [Google Scholar] [CrossRef] [PubMed]
- Enzler, M.J.; Berbari, E.; Osmon, D.R. Antimicrobial prophylaxis in adults. Mayo Clin. Proc. 2011, 86, 686–701. [Google Scholar] [CrossRef] [Green Version]
- Tenke, P.; Kovacs, B.; Bjerklund Johansen, T.E.; Matsumoto, T.; Tambyah, P.A.; Naber, K.G. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int. J. Antimicrob. Agents 2008, 31 (Suppl. S1), S68–S78. [Google Scholar] [CrossRef]
- Baethge, C.; Goldbeck-Wood, S.; Mertens, S. SANRA—A scale for the quality assessment of narrative review articles. Res. Integr. Peer Rev. 2019, 4, 5. [Google Scholar] [CrossRef] [Green Version]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef]
- Banks, J.A.; McGuire, B.B.; Loeb, S.; Shrestha, S.; Helfand, B.T.; Catalona, W.J. Bacteriuria and antibiotic resistance in catheter urine specimens following radical prostatectomy. Urol. Oncol. Semin. Orig. Investig. 2013, 31, 1049–1053. [Google Scholar] [CrossRef]
- Shin, B.; Chung, H.S.; Hwang, E.C.; Jung, S.; Kwon, D.D. Antibiotic prophylaxis in radical prostatectomy: Comparison of 2-day and more than 2-day prophylaxis. J. Korean Med. Sci. 2017, 32, 1009–1015. [Google Scholar] [CrossRef]
- Pinochet, R.; Nogueira, L.; Cronin, A.M.; Katz, D.; Rabbani, F.; Guillonneau, B.; Touijer, K. Role of short-term antibiotic therapy at the moment of catheter removal after laparoscopic radical prostatectomy. Urol. Int. 2010, 85, 415–420. [Google Scholar] [CrossRef] [PubMed]
- Haifler, M.; Mor, Y.; Dotan, Z.; Ramon, J.; Zilberman, D.E. Prophylactic antibiotic treatment following laparoscopic robot-assisted radical prostatectomy for the prevention of catheter-associated urinary tract infections: Did the AUA guidelines make a difference? J. Robot. Surg. 2017, 11, 367–371. [Google Scholar] [CrossRef] [PubMed]
- Berrondo, C.; Feng, C.; Kukreja, J.B.; Messing, E.M.; Joseph, J. Antibiotic prophylaxis at the time of catheter removal after radical prostatectomy: A prospective randomized clinical trial. Urol. Oncol. Semin. Orig. Investig. 2019, 37, 181.e7–181.e14. [Google Scholar] [CrossRef] [PubMed]
- Ehdaie, B.; Jibara, G.; Sjoberg, D.D.; Laudone, V.; Eastham, J.; Touijer, K.; Scardino, P.; Donahue, T.; Goh, A.; Vickers, A. The Duration of Antibiotics Prophylaxis at the Time of Catheter Removal after Radical Prostatectomy: Clinically Integrated, Cluster, Randomized Trial. J. Urol. 2021, 206, 662–668. [Google Scholar] [CrossRef]
- Raz, R.; Elhanan, G.; Almog, D.; Shental, J. The use of ceftriaxone in the prevention of urinary tract infection in patients undergoing transurethral resection of the prostate (TUR-P). Infection 1994, 22, 347–349. [Google Scholar] [CrossRef]
- Hall, J.; Christiansen, K.; England, P.; Low, A.; McRae, P.; Mander, J.; Taylor, T. Antibiotic prophylaxis for patients undergoing transurethral resection of the prostate. Urology 1996, 47, 852–856. [Google Scholar] [CrossRef]
- Chandrasingh, J.; Jayanth, S.T.; Sahni, R.D.; Mukha, R.P.; Kumar, S.; Devasia, A.; Kekre, N.S. Efficacy of 1 versus 3 days of intravenous amikacin as a prophylaxis for patients undergoing transurethral resection of the prostate: A prospective randomized trial. Indian J. Urol. 2021, 37, 133–139. [Google Scholar] [CrossRef]
- Conn, I.G.; Moffat, L.E.F. Short-term cephradine prophylaxis in elective transurethral prostatectomy. J. Hosp. Infect. 1988, 11, 373–375. [Google Scholar] [CrossRef]
- Manjunath, A.; Chen, L.; Welty, L.J.; Wong, V.J.; Amarasekera, C.; Gonzalez, C.M.; Hofer, M.D. Antibiotic prophylaxis after urethroplasty may offer no benefit. World J. Urol. 2020, 38, 1295–1301. [Google Scholar] [CrossRef]
- Baas, W.; Parker, A.; Radadia, K.; Ogawa, S.; Vetter, J.; Paradis, A.; Meyer, M.; Murphy, G. Antibiotic Duration After Urethroplasty: An Attempt at Improving Antibiotic Stewardship. Urology 2021, 158, 228–231. [Google Scholar] [CrossRef]
- Hanasaki, T.; Kanematsu, A.; Yamamoto, S. Proactive discontinuation of postoperative antibiotic prophylaxis after urethroplasty. Int. J. Urol. 2022, 29, 707–711. [Google Scholar] [CrossRef] [PubMed]
- Kim, S.; Cheng, K.C.; Alsikafi, N.F.; Breyer, B.N.; Broghammer, J.A.; Elliott, S.P.; Erickson, B.A.; Myers, J.B.; Smith, T.G.; Vanni, A.J.; et al. Minimizing Antibiotic Use in Urethral Reconstruction. J. Urol. 2022, 208, 128–134. [Google Scholar] [CrossRef] [PubMed]
- Bratzler, D.W.; Dellinger, E.P.; Olsen, K.M.; Perl, T.M.; Auwaerter, P.G.; Bolon, M.K.; Fish, D.N.; Napolitano, L.M.; Sawyer, R.G.; Slain, D.; et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am. J. Health-Syst. Pharm. 2013, 70, 195–283. [Google Scholar] [CrossRef] [Green Version]
- Andretta, E.; Longo, R.; Balladelli, M.; Sgarabotto, C.; Sgarabotto, D. Intravesical Gentamicin: An Option for Therapy and Prophylaxis against Recurrent UTIs and Resistant Bacteria in Neurogenic Bladder Patients on Intermittent Catheterization. Antibiotics 2022, 11, 1335. [Google Scholar] [CrossRef] [PubMed]
- Cox, L.; He, C.; Bevins, J.; Clemens, J.Q.; Stoffel, J.T.; Cameron, A.P. Gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on intermittent catheterization. Can. Urol. Assoc. J. 2017, 11, E350–E354. [Google Scholar] [CrossRef] [PubMed]
- Pietropaolo, A.; Jones, P.; Moors, M.; Birch, B.; Somani, B.K. Use and effectiveness of antimicrobial intravesical treatment for prophylaxis and treatment of recurrent urinary tract infections (UTIs): A systematic review. Curr. Urol. Rep. 2018, 19. [Google Scholar] [CrossRef] [Green Version]
- Cotellese, R.; Ledda, A.; Belcaro, G.; Cesarone, M.R.; Scipione, C.; Scipione, V.; Dugall, M.; Feragalli, B.; Riva, A.; Allegrini, P.; et al. Anthocran® Phytosome®: Prevention of Recurring Urinary Infections and Symptoms after Catheterization. J. Diet. Suppl. 2021, 20, 55–67. [Google Scholar] [CrossRef]
- Lee, B.; Haran, M.J.; Hunt, L.M.; Simpson, J.M.; Marial, O.; Rutkowski, S.B.; Middleton, J.; Kotsiou, G.; Tudehope, M.; Cameron, I.D. Spinal-injured neuropathic bladder antisepsis (SINBA) trial. Spinal Cord 2007, 45, 542–550. [Google Scholar] [CrossRef] [Green Version]
- Falagas, M.E.; Betsi, G.I.; Tokas, T.; Athanasiou, S. Probiotics for Prevention of Recurrent Urinary Tract Infections in Women. Drugs 2006, 66, 1253–1261. [Google Scholar] [CrossRef]
- Toh, S.-L.; Lee, B.B.; Ryan, S.; Simpson, J.M.; Clezy, K.; Bossa, L.; Rice, S.A.; Marial, O.; Weber, G.H.; Kaur, J.; et al. Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: A randomised controlled trial. Spinal Cord 2019, 57, 550–561. [Google Scholar] [CrossRef]
- Lam, T.B.L.; Omar, M.I.; Fisher, E.; Gillies, K.; Maclennan, S. Types of indwelling urethral catheters for short-term catheterisation in hospitalised adults. Cochrane Database Syst. Rev. 2014, 2014, CD004013. [Google Scholar] [CrossRef] [PubMed]
- Talja, M.; Korpela, A.; Järvi, K. Comparison of Urethral Reaction to Full Silicone, Hydrogen-coated and Siliconised Latex Catheters. Br. J. Urol. 1990, 66, 652–657. [Google Scholar] [CrossRef] [PubMed]
- Kazmierska, K.A.; Thompson, R.; Morris, N.; Long, A.; Ciach, T. In vitro multicompartmental bladder model for assessing blockage of urinary catheters: Effect of hydrogel coating on dynamics of proteus mirabilis growth. Urology 2010, 76, e15–e20. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Zhang, S.; Keatch, R.; Corner, G.; Nabi, G.; Murdoch, S.; Davidson, F.; Zhao, Q. In-vitro antibacterial and anti-encrustation performance of silver-polytetrafluoroethylene nanocomposite coated urinary catheters. J. Hosp. Infect. 2019, 103, 55–63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pickard, R.; Lam, T.; MacLennan, G.; Starr, K.; Kilonzo, M.; McPherson, G.; Gillies, K.; McDonald, A.; Walton, K.; Buckley, B.; et al. Types of urethral catheter for reducing symptomatic urinary tract infections in hospitalised adults requiring short-term catheterisation: Multicentre randomised controlled trial and economic evaluation of antimicrobial- and antisepticimpregnated urethral catheters (the CATHETER trial). Health Technol. Assess. 2012, 16, 1–197. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kunin, C.M.; Chin, Q.F.; Chambers, S. Formation of encrustations on indwelling urinary catheters in the elderly: A comparison of different types of catheter materials in “blockers” and “nonblockers” . J. Urol. 1987, 138, 899–902. [Google Scholar] [CrossRef]
- Karchmer, T.B.; Giannetta, E.T.; Muto, C.A.; Strain, B.A.; Farr, B.M. A randomized crossover study of silver-coated urinary catheters in hospitalized patients. Arch. Intern. Med. 2000, 160, 3294–3298. [Google Scholar] [CrossRef]
- Lai, K.K.; Fontecchio, S.A. Use of silver-hydrogel urinary catheters on the incidence of catheter-associated urinary tract infections in hospitalized patients. Am. J. Infect. Control. 2002, 30, 221–225. [Google Scholar] [CrossRef]
- Bonfill, X.; Rigau, D.; Esteban-Fuertes, M.; Barrera-Chacón, J.M.; Jáuregui-Abrisqueta, M.L.; Salvador, S.; Alemán-Sánchez, C.M.; Borau, A.; Bea-Muñoz, M.; Hidalgo, B.; et al. Efficacy and safety of urinary catheters with silver alloy coating in patients with spinal cord injury: A multicentric pragmatic randomized controlled trial. The ESCALE trial. Spine J. 2017, 17, 1650–1657. [Google Scholar] [CrossRef]
- Bonfill, X.; Rigau, D.; Esteban-Fuertes, M.; Barrera-Chacón, J.M.; Jáuregui-Abrisqueta, M.L.; Salvador, S.; Alemán-Sánchez, C.M.; Borau, A.; Bea-Muñoz, M.; Hidalgo, B.; et al. Bioengineered phytomolecules-capped silver nanoparticles using Carissa carandas leaf extract to embed on to urinary catheter to combat UTI pathogens. PLoS ONE 2021, 16, e0256748. [Google Scholar] [CrossRef]
- Thomas-White, K.J.; Gao, X.; Lin, H.; Fok, C.S.; Ghanayem, K.; Mueller, E.R.; Dong, Q.; Brubaker, L.; Wolfe, A.J. Urinary microbes and postoperative urinary tract infection risk in urogynecologic surgical patients. Int. Urogynecol. J. 2018, 29, 1797–1805. [Google Scholar] [CrossRef] [PubMed]
- Groah, S.L.; Pérez-Losada, M.; Caldovic, L.; Ljungberg, I.H.; Sprague, B.M.; Castro-Nallar, E.; Chandel, N.J.; Hsieh, M.H.; Pohl, H. Redefining Healthy Urine: A Cross-Sectional Exploratory Metagenomic Study of People With and Without Bladder Dysfunction. J. Urol. 2016, 196, 579–587. [Google Scholar] [CrossRef] [PubMed]
- Darouiche, R.O.; Green, B.G.; Donovan, W.H.; Chen, D.; Schwartz, M.; Merritt, J.; Mendez, M.; Hull, R.A. Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder. Urology 2011, 78, 341–346. [Google Scholar] [CrossRef] [PubMed]
Association | Asymptomatic Bacteriuria (ASB) | Catheter-Associated Bacteriuria (CAB) | Urinary Tract Infection (UTI) | Catheter-Associated UTI (CAUTI) |
---|---|---|---|---|
Infectious Diseases Society of America (IDSA) | ≥1 species of bacteria growing in voided urine specimen at ≥105 CFU/mL (or ≥108 CFU/L), irrespective of the presence of pyuria, in the absence of signs or symptoms attributable to UTI. For women, two consecutive specimens should be obtained, preferably within two weeks. For men, a single urine specimen is sufficient [12]. | ≥1 species of bacteria growing in a single urine specimen obtained from indwelling catheter at ≥105 CFU/mL, in the absence of signs or symptoms attributable to UTI [7,12]. | Not specifically defined in available guidelines. | Presence of signs or symptoms compatible with UTI with no other identified source of infection along with ≥103 CFU/mL of 1 bacterial species in a single catheter urine specimen or in a midstream voided urine specimen from a patient whose urethral, suprapubic, or condom catheter has been removed within the previous 48 h [7]. |
European Association of Urology (EUA) | A mid-stream sample of urine showing bacterial growth > 105 CFU/mL in two consecutive voided samples in women or in one single sample in men, in the absence of signs or symptoms attributable to UTI. In a single catheterized sample, bacterial growth may be as low as 102 CFU/mL [8]. | Not specifically defined in available guidelines. | The diagnosis of uncomplicated cystitis can be made based on a focused history of lower urinary tract symptoms (dysuria, frequency and urgency) and in the absence of vaginal discharge. CFU not clearly defined [8]. | Microbial growth of >103 CFU/mL of ≥1 bacterial species in a single catheter urine specimen or in a mid-stream voided urine specimen from a patient whose urethral, suprapubic, or condom catheter has been removed within the previous 48 h [8]. |
Center for Disease Control (CDC) | The presence of bacteria in urine. CFU not clearly defined [22]. | The presence of bacteria in a urine sample due to bacterial colonization of the urinary tract and/or indwelling urinary catheter. This does not cause symptoms [22]. | Patient must meet 1, 2, and 3 below: 1. One of the following is true: • Patient has/had an indwelling urinary catheter, but it has/had not been in place for more than two consecutive days in an inpatient location on the date of event, OR • Patient did not have an indwelling urinary catheter in place on the date of event nor the day before the date of event. 2. Patient has at least one of the following signs or symptoms: • fever (>38 °C) • suprapubic tenderness • costovertebral angle pain or tenderness • urinary frequency • urinary urgency • dysuria 3. Patient has a urine culture with no more than two species of organisms identified, at least one of which is a bacterium of ≥105 CFU/mL [23]. | Patient must meet 1, 2, and 3 below: 1. Patient had an indwelling urinary catheter that had been in place for more than 2 consecutive days in an inpatient location on the date of event AND was either: • Present for any portion of the calendar day on the date of event, OR • Removed the day before the date of event. 2. Patient has at least one of the following signs or symptoms: • fever (>38.0 °C) • suprapubic tenderness • costovertebral angle pain or tenderness • urinary urgency • urinary frequency • dysuria 3. Patient has a urine culture with no more than two species of organisms identified, at least one of which is a bacterium of ≥105 CFU/mL [23]. |
American Urological Association (AUA) | Presence of bacteria in the urine that causes no symptoms [24]. | Not specifically defined in available publications. | Symptoms plus 105 CFU/mL of bacteria on a clean catch specimen, or 103 CFU/mL on a catheterized specimen [25]. | A UTI that occurs after a catheter has been left in place for 48 h [25]. |
Association | Continuous Antibiotic Prophylaxis during Routine Catheterization | Continuous Antibiotic Prophylaxis during Post-Operative Catheterization | Antibiotic Prophylaxis at the Time of Routine Catheter Removal | Antibiotic Prophylaxis at the Time of Post-Operative Catheter Removal |
---|---|---|---|---|
Infectious Diseases Society of America (IDSA) | Recommend against [7]. | Recommend against [7]. | Recommend against [7]. | Recommend against [7]. |
European Association of Urology (EUA) | Recommend against [8]. | Not specified [8]. | Recommend against [8]. | Not specified [8]. |
Center for Disease Control (CDC) | Recommend against [6]. | Not specified [6]. | Recommend against [6]. | Consider in certain settings.
|
American Urological Association (AUA) | Not specified [11]. | Not specified [11]. | Consider in certain settings.
| Consider in certain settings.
|
Study Publication | Study Design | Procedure | Number of Patients Analyzed | Interventions | Outcome Results |
---|---|---|---|---|---|
Banks et al. 2013 [33] | Prospective Descriptive Single-center | Radical Prostatectomy | 334 | (1) prophylactic antibiotics (oral ciprofloxacin) for 7 days starting night before catheter removal (n = 334) | 83 (25%) of patients had positive urine culture results at time of catheter removal, of which 7% were resistant to ciprofloxacin. 2 (0.6%) patients developed symptoms of UTI. |
Shin et al. 2017 [34] | Retrospective Cohort Single-center | Radical Prostatectomy | 313 | (1) prophylactic antibiotics (cephalosporin) administered < 2 days (n = 153) (2) prophylactic antibiotics (cephalosporin) administered > 2 days (n = 160) | Postoperative bacteriuria at time of catheter removal was significantly higher in group 1 (56.9%) than in group 2 (45%). Fever (>38 °C) was similar (group 1 with 4 fevers, group 2 with 3 fevers). |
Pinochet et al. 2010 [35] | Retrospective Cohort Single-center | Radical Prostatectomy | 713 | (1) prophylactic antibiotics (oral ciprofloxacin) for 3 days starting night before catheter removal (n = 261) (2) no antibiotics (n = 452) | UTI less common in group 1 (3.1%) than group 2 (7.3%). Fever less common in group 1 (0%) than group 2 (2.4%). |
Haifler et al. 2017 [36] | Retrospective Cohort Single-center | Radical Prostatectomy | 229 | (1) perioperative prophylactic antibiotics, daily until catheter removal (n = 60) (2) perioperative antibiotics only (n = 129) (Cephalosporin and Aminoglycoside) | CAUTI rate was similar in both groups (8.3 vs. 8.9%, respectively, p = 0.89). Logistic regression analysis showed no association between treatment protocol and potential risk for CAUTI. |
Berrondo et al. 2019 [37] | Prospective RCT Single-center | Radical Prostatectomy | 167 | (1) prophylactic antibiotics given prior to urinary catheter removal (2 doses of oral ciprofloxacin, evening prior and morning of) (n = 83) (2) no antibiotics (n = 84) | 8 (4.8%) patients developed symptomatic UTI within 6 weeks of urinary catheter removal. No significant difference in the rate of UTI between the control group and antibiotic prophylaxis group (5.95% vs. 6.02%, p = 1). No significant difference in the rates of C difficile infection between the control and the antibiotic prophylaxis groups (3.57% vs. 0%, p = 0.21). |
Ehdaie et al. 2021 [38] | Prospective RCT | Radical Prostatectomy | 824 | (1) 1 day regimen of prophylactic antibiotics at the time of catheter removal (n = 389) (2) 3 day regimen of prophylactic antibiotics at the time of catheter removal (n = 435) Ciprofloxacin predominantly used. | 0 UTI (0%) in the 1-day regimen and 3 UTI (0.7%) in the 3-day regimen. Declared the 1-day regimen to be non-inferior. |
Raz et al. 1994 [39] | Prospective RCT Single-center | TURP | 101 | (1) antibiotic prophylaxis (ceftriaxone 1 g IV perioperatively and 3–4 days postoperatively at time of catheter removal) (n = 51) (2) no antibiotics (n = 50) | Fever (> 38.5 C) did not occur in any patient who received antibiotic prophylaxis, but developed in 6 (12%) of the control patients. Duration of fever was also considerably shorter in ceftriaxone treated patients: 10 of 51 had fever more than 2 days vs. 19 of 50 (38%) control patients. Of the six patients in the ceftriaxone group who developed bacteriuria, only three were symptomatic and required antimicrobial therapy. In contrast, 14 of the 20 control patients who were bacteriuric, were symptomatic (p < 0.005) |
Hall et al. 1996 [40] | Prospective RCT Single-center | TURP | 84 | (1) single perioperative oral dose of fleroxacin (n = 28) (2) single perioperative IV dose of fleroxacin (n = 29) (3) initial perioperative IV dose of fleroxacin followed by daily oral fleroxacin until removal of the urinary catheter (up to 6 days) (n = 27) | Only one patient developed a UTI (single dose IV group), which occurred 22 days post-operatively. There were no instances of urosepsis nor was there a significant difference in rates of fever between groups. |
Jayanth et al. 2021 [41] | Prospective RCT Single-center | TURP | 314 | (1) perioperative IV amikacin (15 mg/kg) (n = 158) (2) IV amikacin for 3 days until catheter removal (n = 156) | No significant difference between groups in rates of bacteriuria and symptomatic UTI up to 3 weeks after surgery. The rates of antibiotic resistance were significantly greater in the group which received 3 days of antibiotics. |
Conn et al. 1988 [42] | Prospective RCT Single-center | TURP | 142 | (1) antibiotic prophylaxis (cephradine 1.5 g IV perioperatively and 1 g orally 3–4 days postoperatively at time of catheter removal) (n = 74) (2) no antibiotics (n = 68) | No significant difference in rates of fever (37.2 C) or UTI (defined as urine culture growth of >100,000 CFU of a single organism). |
McDonald et al. 2016 [2] | Cross sectional survey | Urethroplasty | 34 | 27-question survey administered to international members of the Society of Genitourinary Reconstructive Surgeons (GURS) | The majority of reconstruction urologists indicated they would administer prophylactic antibiotics for as long as the catheter is in place. 60.1% selected nitrofurantoin and 21.2% answered fluoroquinolone. The majority stated they give additional antibiotics at the time of catheter removal regardless of a culture 69.7% |
Hoare et al. 2021 [3] | Cross sectional survey | Urethroplasty | 142 | An online survey examining perioperative management of anterior urethroplasty administered to Society of Genitourinary Reconstructive Surgeons (GURS) members. | Postoperatively, oral antimicrobials are routinely administered (70.4%), with most continuing until the urinary catheter is removed (72.2%). |
Manjunath et al. 2020 [43] | Retrospective Descriptive Single-center | Urethroplasty | 398 | All patients received preoperative antibiotic prophylaxis and postoperative prophylaxis for 30 days or until catheter removal. Cultures were collected if there was concern for UTI symptoms. | Identified 102 (25.6%) positive urine cultures (defined as > 1000 CFU/mL of an organism) within 30 days of urethroplasty. There were no significant differences in stricture recurrence (p = 0.36) or wound complications (p = 0.42) between patients who had a positive and negative urine culture. On multivariate analysis, positive urine cultures (hazard ratio 1.0, 95% confidence interval 0.6–1.8, p = 0.88) were not associated with stricture recurrence. |
Baas et al. 2021 [44] | Retrospective Descriptive Single-center | Urethroplasty | 120 | (1) extended postop antibiotic prophylaxis for 3 weeks until catheter removal (n = 60) (2) antibiotic for 3 days starting day before catheter removal (n = 60) (sulfamethoxazole- trimethoprim 800 mg/ 160 mg twice daily, or cephalexin 500 mg every 8 h) | 10 patients had UTIs after urethroplasty. There was no significant difference in UTI (6.7% vs. 11.7%; p = 0.529) or wound infection rates (3.3% vs. 1.7%; p = 1.000) between the two groups. |
Kim et al. 2022 [46] | Prospective Multi-center | Urethroplasty or Perineal urethrostomy | 900 | (1) prolonged postoperative antibiotics (macrobid 100 mg BID or keflex until catheter removal, plus 2 doses of ciprofloxacin 500 mg or trimethoprim-sulfamethoxazole DS around day of catheter removal) (n = 390) (2) antibiotics at time of catheter removal only (2 dosages of ciprofloxacin or trimethoprim-sulfamethoxazole) (n = 510) | Rate of post-operative UTI and wound infection within 30 days was 5.1% (6.7% for cohort 1 vs. 3.9% for cohort 2, p = 0.064) and 3.9% (4.1% for cohort 1 vs. 3.7% for cohort 2, p = 0.772) |
Hanasaki et al. 2022 [45] | Retrospective Descriptive Single-center | Urethroplasty | 81 | All patients were treated with intravenous antimicrobial agents until postoperative day 2. Antibiotics were resumed the day before urethral catheter removal, 2–3 weeks postoperatively. Antibiotics were then continued for another 3 to 4 days after. | Approximately half of the patients had a positive urine culture postoperatively. Wound infections and symptomatic urinary tract infections rates were 3.7% and 2.5%, respectively. No significant correlation was noted with pre- and postoperative positive urine culture. The overall clinical and objective success rates were 96.3% and 79.0%, respectively, and no significant impact of pre- or postoperative positive urine culture was noted. |
Intervention | Summary of Findings | Future Directions |
---|---|---|
Antibiotic Bladder Irrigations | Patients who perform clean intermittent catheterization who experience recurrent lower UTIs may have reduction in UTI frequency when treated with intravesical Gentamicin [48]. They may also undergo fewer courses of oral antibiotics, and demonstrate less MDR organisms in urine cultures [49]. The side effects are minor [50]. | Study utility of antibiotic bladder irrigations in the context of post-procedural catheterization. Study which antibiotic agents are most effective for intravesical irrigations. Compare outcomes of different regimens/frequencies of antibiotic irrigations. |
Supplements | Cranberry supplements have been used at UTI prophylaxis in patients who underwent a surgical procedure and required temporary urinary catheterization during the perioperative period. After 4 weeks, the supplement demonstrated a decrease in the occurrence of UTI symptoms, hematuria, and bacteriuria [51]. When studied in patients with neuropathic bladder following spinal cord injury with stable bladder management (indwelling urethral or suprapubic catheter, intermittent catheterization, or reflex voiding with or without a condom drainage device), Methenamine Hippurate (MH) or cranberry supplements did not result in a significantly longer UTI-free period compared to placebo [52]. There are encouraging articles demonstrating the effectiveness and safety of probiotics (with certain strains of lactobacilli) for prophylaxis against uncomplicated UTI [53]. When studied in patients with spinal cord injury, prophylactic Lactobacillus strains did not prevent UTI with more frequency than placebo [54]. | Demonstrate a consistent benefit from supplements in the prevention of complex urinary tract infection, in patients with and without catheters. If this can be established, then investigate potential in the post-operative setting. |
Catheter selection | There has been inconsistent data regarding benefits of various catheter materials. At present, silicone catheters may be preferred based on equivalent or better outcomes at lower cost. Usage of silicone catheters may result in decreased urethral inflammation and encrustation when compared to other materials [55,56]. Hydrogel-coated catheters aggregate cells and crystals in vitro, leading to catheter blockage [57]. Polytetrafluoroethylene (PTFE), also known as Teflon®, coated catheters, inhibit bacterial migration and biofilm formation in vitro [58]. A large RCT compared rates of UTI that occurred following in-strumentation with Teflon-coated silicone catheters vs. nitrofu-razone-coated catheters or silver alloy catheters. They did not find clinically significance difference in rates of UTI between these groups [59]. A trial found PTFE catheters and latex catheters to be associated with increased encrustation compared to those made of silicone [60]. A randomized crossover study found a decreased rate of CAUTI in patients who were randomized to silver-coated catheters ver-sus those with uncoated catheters [61]. Other studies did not demonstrate protective benefit in reduction of CAUTI [62,63]. There has been published preliminary data showing catheters embedded with bioengineered phytomolecules-capped silver nanoparticles may preventing invasion and colonization of uro-pathogens [64]. | Explore phytomolecules/nano particles for more effective antimicrobial and anti-encrustation. |
Alteration of the urinary microbiome | Patients with decreased proportions of Lactobacillus and an increased number of uropathogens in their pre-operative urinary microbiome have increased risk of post-operative UTI [65]. One technique to alter the microbiome may involve deliberately colonizing the bladder with bacterial interference [66]. Investigators inoculated the bladders of patients with spinal cord injury with a particular strain of E. Coli. These patients had less symptomatic UTI compared to controls [67]. | Investigate the urinary microbiome, and how it differs in patients who experience recurrent UTI. Explore how urinary microbiome may be altered with catheterization. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Maffucci, F.; Chang, C.; Simhan, J.; Cohn, J.A. Is There Any Benefit to the Use of Antibiotics with Indwelling Catheters after Urologic Surgery in Adults. Antibiotics 2023, 12, 156. https://doi.org/10.3390/antibiotics12010156
Maffucci F, Chang C, Simhan J, Cohn JA. Is There Any Benefit to the Use of Antibiotics with Indwelling Catheters after Urologic Surgery in Adults. Antibiotics. 2023; 12(1):156. https://doi.org/10.3390/antibiotics12010156
Chicago/Turabian StyleMaffucci, Fenizia, Chrystal Chang, Jay Simhan, and Joshua A. Cohn. 2023. "Is There Any Benefit to the Use of Antibiotics with Indwelling Catheters after Urologic Surgery in Adults" Antibiotics 12, no. 1: 156. https://doi.org/10.3390/antibiotics12010156
APA StyleMaffucci, F., Chang, C., Simhan, J., & Cohn, J. A. (2023). Is There Any Benefit to the Use of Antibiotics with Indwelling Catheters after Urologic Surgery in Adults. Antibiotics, 12(1), 156. https://doi.org/10.3390/antibiotics12010156